Last reviewed 2026-04-19 · How we verify

R-Star001

changjianhua · Phase 1 active Small molecule

R-Star001 is a Small molecule drug developed by changjianhua. It is currently in Phase 1 development.

At a glance

Generic name	R-Star001
Sponsor	changjianhua
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Treating Nectin-4-positive Advanced Solid Tumors With R-Star001 (Nectin-4-CART-IL18) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

R-Star001 CI brief — competitive landscape report
R-Star001 updates RSS · CI watch RSS
changjianhua portfolio CI

Frequently asked questions about R-Star001

What is R-Star001?

R-Star001 is a Small molecule drug developed by changjianhua.

Who makes R-Star001?

R-Star001 is developed by changjianhua (see full changjianhua pipeline at /company/changjianhua).

What development phase is R-Star001 in?

R-Star001 is in Phase 1.

Manufacturer: changjianhua — full pipeline
Compare: R-Star001 vs similar drugs
Pricing: R-Star001 cost, discount & access